Skip to main content
SpringerLink
Log in

Alcoholic Liver Disease

  • Chapter
  • First Online:
Liver Disorders

Abstract

Alcoholic liver disease (ALD) is a major cause of morbidity and mortality worldwide. The clinical spectrum of ALD includes fatty liver, steatohepatitis with or without fibrosis, and cirrhosis. Severe Alcoholic Hepatitis (AH) is an especially important cause of morbidity, mortality, and health care costs in the United States (U.S.) and worldwide. The diagnosis of ALD is made in patients with evidence of liver injury based on clinical history, physical findings, and laboratory abnormalities, when there is evidence of significant alcohol consumption and after other causes of chronic liver disease have been excluded. Problems diagnosing the disease arise when the patient exhibits no symptoms or clinical findings, risk factors for other liver diseases, or when the patient conceals alcohol abuse. The goal of this chapter is to review: (1) selected mechanisms of liver toxicity, (2) the clinical features of ALD, (3) the natural history and prognostic factors, and (4) potential therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carithers RL, McClain CJ. Alcoholic liver disease. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease, vol. 2. Philadelphia, PA: Elsevier Saunders; 2016. p. 1409–27.

    Google Scholar 

  2. Liangpunsakul S. Clinical characteristics and mortality of hospitalized alcoholic hepatitis patients in the United States. J Clin Gastroenterol. 2011;45(8):714–9. PubMed PMID: 21085006, PubMed Central PMCID: 3135756.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sandahl TD, Jepsen P, Thomsen KL, Vilstrup H. Incidence and mortality of alcoholic hepatitis in Denmark 1999-2008: a nationwide population based cohort study. J Hepatol. 2011;54(4):760–4.

    Article  PubMed  Google Scholar 

  4. Chedid A, Mendenhall CL, Gartside P, French SW, Chen T, Rabin L. Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol. 1991;86(2):210–6.

    CAS  PubMed  Google Scholar 

  5. Beier JI, McClain CJ. Mechanisms and cell signaling in alcoholic liver disease. Biol Chem. 2010;391(11):1249–64. PubMed PMID: 20868231, PubMed Central PMCID: 3755482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res. 1995;19(3):635–41.

    Article  CAS  PubMed  Google Scholar 

  7. Zhong W, Zhao Y, Sun X, Song Z, McClain CJ, Zhou Z. Dietary zinc deficiency exaggerates ethanol-induced liver injury in mice: involvement of intrahepatic and extrahepatic factors. PLoS One. 2013;8(10):e76522. PubMed PMID: 24155903, PubMed Central PMCID: 3796541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract. 2012;27(1):8–20.

    Article  PubMed  Google Scholar 

  9. Kirpich IA, Feng W, Wang Y, Liu Y, Barker DF, Barve SS, et al. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res. 2012;36(5):835–46. PubMed PMID: 22150547, PubMed Central PMCID: 3319492.

    Article  CAS  PubMed  Google Scholar 

  10. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol. 2008;42(5):349–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Gustot T, Lemmers A, Moreno C, Nagy N, Quertinmont E, Nicaise C, et al. Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology. 2006;43(5):989–1000.

    Article  CAS  PubMed  Google Scholar 

  12. Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, et al. Innate immunity in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2011;300(4):G516–25. PubMed PMID: 21252049, PubMed Central PMCID: 3774265.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513–24. PubMed PMID: 24440671, PubMed Central PMCID: 3996054.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, et al. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8(1):e53028. PubMed PMID: 23326376, PubMed Central PMCID: 3541399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shi X, Wei X, Yin X, Wang Y, Zhang M, Zhao C, et al. Hepatic and fecal metabolomic analysis of the effects of lactobacillus rhamnosus GG on alcoholic fatty liver disease in mice. J Proteome Res. 2015;14(2):1174–82.

    Article  CAS  PubMed  Google Scholar 

  16. Esfandiari F, Villanueva JA, Wong DH, French SW, Halsted CH. Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005;289(1):G54–63.

    Article  CAS  PubMed  Google Scholar 

  17. Galligan JJ, Smathers RL, Shearn CT, Fritz KS, Backos DS, Jiang H, et al. Oxidative Stress and the ER stress response in a murine model for early-stage alcoholic liver disease. J Toxicol. 2012;2012:207594. PubMed PMID: 22829816, PubMed Central PMCID: 3399426.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Tsedensodnom O, Vacaru AM, Howarth DL, Yin C, Sadler KC. Ethanol metabolism and oxidative stress are required for unfolded protein response activation and steatosis in zebrafish with alcoholic liver disease. Dis Model Mech. 2013;6(5):1213–26. PubMed PMID: 23798569, PubMed Central PMCID: 3759341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tsuchiya M, Ji C, Kosyk O, Shymonyak S, Melnyk S, Kono H, et al. Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology. 2012;56(1):130–9. PubMed PMID: 22307928, PubMed Central PMCID: 3350836.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ramirez T, Tong M, Chen WC, Nguyen QG, Wands JR, de la Monte SM. Chronic alcohol-induced hepatic insulin resistance and endoplasmic reticulum stress ameliorated by peroxisome-proliferator activated receptor-delta agonist treatment. J Gastroenterol Hepatol. 2013;28(1):179–87. PubMed PMID: 22988930, PubMed Central PMCID: 4406771.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tong M, Longato L, Ramirez T, Zabala V, Wands JR, de la Monte SM. Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin. Int J Exp Pathol. 2014;95(1):49–63. PubMed PMID: 24456332, PubMed Central PMCID: 3919649.

    Article  CAS  PubMed  Google Scholar 

  22. Dimova EY, Kietzmann T. Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver. Thromb Haemost. 2008;100(6):992–1006.

    CAS  PubMed  Google Scholar 

  23. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol. 2006;41(3):209–24.

    Article  CAS  PubMed  Google Scholar 

  24. Mendenhall CL. Alcoholic hepatitis. Clin Gastroenterol. 1981;10(2):417–41.

    CAS  PubMed  Google Scholar 

  25. Lischner MW, Alexander JF, Galambos JT. Natural history of alcoholic hepatitis. I. The acute disease. Am J Dig Dis. 1971;16(6):481–94.

    Article  CAS  PubMed  Google Scholar 

  26. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17.

    Article  PubMed  Google Scholar 

  27. Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009;24(7):783–8. PubMed PMID: 19247718, PubMed Central PMCID: 2695521.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA. 1984;252(14):1905–7.

    Article  CAS  PubMed  Google Scholar 

  29. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23(5):1025–9.

    Article  CAS  PubMed  Google Scholar 

  30. Crabb DW. Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio J Med. 1999;48(4):184–8.

    Article  CAS  PubMed  Google Scholar 

  31. Van Thiel DH, Gavaler JS, Schade RR. Liver disease and the hypothalamic pituitary gonadal axis. Semin Liver Dis. 1985;5(1):35–45.

    Article  PubMed  Google Scholar 

  32. Dutta SK, Dukehart M, Narang A, Latham PS. Functional and structural changes in parotid glands of alcoholic cirrhotic patients. Gastroenterology. 1989;96(2 Pt 1):510–8.

    Article  CAS  PubMed  Google Scholar 

  33. Pirovino M, Linder R, Boss C, Kochli HP, Mahler F. Cutaneous spider nevi in liver cirrhosis: capillary microscopical and hormonal investigations. Klin Wochenschr. 1988;66(7):298–302.

    Article  CAS  PubMed  Google Scholar 

  34. Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, et al. Dupuytren’s contracture, alcohol consumption, and chronic liver disease. Arch Intern Med. 1987;147(6):1065–7.

    Article  CAS  PubMed  Google Scholar 

  35. Epstein O, Dick R, Sherlock S. Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease. Gut. 1981;22(3):203–6. PubMed PMID: 7227854, PubMed Central PMCID: 1419499.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: a study of 502 patients admitted consecutively to a medical department. Alcohol Clin Exp Res. 1994;18(5):1103–8.

    Article  CAS  PubMed  Google Scholar 

  37. Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pecoud A. Screening for excessive alcohol drinking. Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Arch Intern Med. 1995;155(17):1907–11.

    Article  CAS  PubMed  Google Scholar 

  38. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med. 1989;111(6):473–8.

    Article  PubMed  Google Scholar 

  39. Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015;12(4):231–42.

    Article  PubMed  Google Scholar 

  40. Pateria P, de Boer B, MacQuillan G. Liver abnormalities in drug and substance abusers. Best Pract Res Clin Gastroenterol. 2013;27(4):577–96.

    Article  CAS  PubMed  Google Scholar 

  41. Mathurin P, Beuzin F, Louvet A, Carrie-Ganne N, Balian A, Trinchet JC, et al. Fibrosis progression occurs in a subgroup of heavy drinkers with typical histological features. Aliment Pharmacol Ther. 2007;25(9):1047–54.

    Article  CAS  PubMed  Google Scholar 

  42. Rubin E, Lieber CS. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med. 1968;278(16):869–76.

    Article  CAS  PubMed  Google Scholar 

  43. Lieber CS, Rubin E. Alcoholic fatty liver in man on a high protein and low fat diet. Am J Med. 1968;44(2):200–6.

    Article  CAS  PubMed  Google Scholar 

  44. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis. 1986;6(3):221–32.

    Article  CAS  PubMed  Google Scholar 

  45. Ma C, Brunt EM. Histopathologic evaluation of liver biopsy for cirrhosis. Adv Anat Pathol. 2012;19(4):220–30.

    Article  PubMed  Google Scholar 

  46. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572–85. PubMed PMID: 21920463, PubMed Central PMCID: 3214974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Said A, Holden JP, Williams JB, Musat A, Botero RC, Lucey MR. Model for end stage liver disease (MELD) scores predict mortality across a broad spectrum of liver disease in a us tertiary care-setting. Gastroenterology. 2003;124(4):A690–1.

    Article  Google Scholar 

  48. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.

    Article  CAS  PubMed  Google Scholar 

  49. Freeman Jr RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002;8(9):851–8.

    Article  PubMed  Google Scholar 

  50. Maddrey WC, Boitnott JK, Bedine MS, Weber Jr FL, Mezey E, White Jr RI. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75(2):193–9.

    CAS  PubMed  Google Scholar 

  51. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut. 1982;23(1):75–9. PubMed PMID: 7035299, PubMed Central PMCID: 1419581.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Carithers Jr RL, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med. 1989;110(9):685–90.

    Article  PubMed  Google Scholar 

  53. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut. 2005;54(8):1174–9. PubMed PMID: 16009691, PubMed Central PMCID: 1774903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103(11):2747–56.

    Article  PubMed  Google Scholar 

  55. Lille Model http://www.lillemodel.com/score.asp2015 (cited 2015 April 7, 2015).

  56. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology. 2007;45(6):1348–54.

    Article  CAS  PubMed  Google Scholar 

  57. Lucey MR. Management of alcoholic liver disease. Clin Liver Dis. 2009;13(2):267–75.

    Article  PubMed  Google Scholar 

  58. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. I. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease: effects on drinking behavior by nurse/physician teams. Alcohol Clin Exp Res. 2003;27(11):1757–64.

    Article  CAS  PubMed  Google Scholar 

  59. Muzyk AJ, Rivelli SK, Gagliardi JP. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence. CNS Drugs. 2012;26(1):69–78.

    Article  CAS  PubMed  Google Scholar 

  60. Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol. 1992;136(10):1248–57.

    Article  CAS  PubMed  Google Scholar 

  61. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 2002;35(3):635–8.

    Article  PubMed  Google Scholar 

  62. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology. 1993;17(4):564–76.

    Article  CAS  PubMed  Google Scholar 

  63. McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93(11):2022–36.

    Article  CAS  PubMed  Google Scholar 

  64. McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease and malnutrition. Alcohol Clin Exp Res. 2011;35(5):815–20.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin Liver Dis. 2012;16(4):805–26.

    Article  PubMed  Google Scholar 

  66. Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009;29(9):1396–402.

    Article  PubMed  Google Scholar 

  67. Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 2012;10(2):117–25.

    Article  PubMed  Google Scholar 

  68. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25(2):285–94.

    Article  CAS  PubMed  Google Scholar 

  69. Plank LD, Gane EJ, Peng S, Muthu C, Mathur S, Gillanders L, et al. Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial. Hepatology. 2008;48(2):557–66.

    Article  PubMed  Google Scholar 

  70. Schulz GJ, Campos AC, Coelho JC. The role of nutrition in hepatic encephalopathy. Curr Opin Clin Nutr Metab Care. 2008;11(3):275–80.

    Article  PubMed  Google Scholar 

  71. Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135(6):1953–60. PubMed PMID: 18848937, PubMed Central PMCID: PMC2639749.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. Veterans Affairs Cooperative Study G. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765–72.

    Article  CAS  PubMed  Google Scholar 

  73. Mezey E, Potter JJ, Rennie-Tankersley L, Caballeria J, Pares A. A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. J Hepatol. 2004;40(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  74. Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, et al. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology. 2005;128(4):882–90.

    Article  CAS  PubMed  Google Scholar 

  75. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial. J Hepatol. 2006;44(4):784–90.

    Article  CAS  PubMed  Google Scholar 

  76. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease--a Cochrane Hepato-Biliary Group Review. Liver. 2001;21(6):398–404.

    Article  CAS  PubMed  Google Scholar 

  77. Stewart S, Prince M, Bassendine M, Hudson M, James O, Jones D, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol. 2007;47(2):277–83.

    Article  CAS  PubMed  Google Scholar 

  78. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(6):1637–48.

    Article  CAS  PubMed  Google Scholar 

  79. De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol. 2009;15(13):1613–9. PubMed PMID: 19340904, PubMed Central PMCID: 2669113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Gobejishvili L, Crittenden N, Mcclain C. Controversies in hepatology: the experts analyze both sides. Thorofare, NJ: Slack, Inc.; 2011. p. 3–10.

    Google Scholar 

  81. De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol Endocrinol. 2009;23(3):281–91.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet. 2009;373(9678):1905–17.

    Article  CAS  PubMed  Google Scholar 

  83. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522–43.

    Article  CAS  PubMed  Google Scholar 

  84. Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203(1):7–13. PubMed PMID: 16380507, PubMed Central PMCID: 2118081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967–76.

    Article  CAS  PubMed  Google Scholar 

  86. Wang FF, Zhu LA, Zou YQ, Zheng H, Wilson A, Yang CD, et al. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R103. PubMed PMID: 22551315, PubMed Central PMCID: 3446480.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. di Mambro AJ, Parker R, McCune A, Gordon F, Dayan CM, Collins P. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. Hepatology. 2011;53(4):1316–22.

    Article  PubMed  CAS  Google Scholar 

  88. Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol. 2010;120(2-3):76–85.

    Article  CAS  PubMed  Google Scholar 

  89. Rajendrasozhan S, Yang SR, Edirisinghe I, Yao H, Adenuga D, Rahman I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid Redox Signal. 2008;10(4):799–811. PubMed PMID: 18220485, PubMed Central PMCID: 2758554.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Rogatsky I, Ivashkiv LB. Glucocorticoid modulation of cytokine signaling. Tissue Antigens. 2006;68(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  91. Hearing SD, Norman M, Probert CS, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45(3):382–8. PubMed PMID: 10446106, PubMed Central PMCID: 1727659.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Kendrick SF, Henderson E, Palmer J, Jones DE, Day CP. Theophylline improves steroid sensitivity in acute alcoholic hepatitis. Hepatology. 2010;52(1):126–31.

    Article  CAS  PubMed  Google Scholar 

  93. Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology. 2003;38(6):1363–9.

    Article  CAS  PubMed  Google Scholar 

  94. Mathurin P, O’Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255–60.

    Article  CAS  PubMed  Google Scholar 

  95. Rambaldi A, Saconato HH, Christensen E, Thorlund K, Wetterslev J, Gluud C. Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther. 2008;27(12):1167–78.

    Article  CAS  PubMed  Google Scholar 

  96. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9(3):349–51.

    Article  CAS  PubMed  Google Scholar 

  97. Taguchi I, Oka K, Kitamura K, Sugiura M, Oku A, Matsumoto M. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis. Inflamm Res. 1999;48(7):380–5.

    Article  CAS  PubMed  Google Scholar 

  98. Gouillon ZQ, Miyamoto K, Donohue TM, Wan YJ, French BA, Nagao Y, et al. Role of CYP2E1 in the pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitin-proteasome pathway. Front Biosci. 1999;4:A16–25.

    Article  CAS  PubMed  Google Scholar 

  99. Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 2008;295(4):G718–24. PubMed PMID: 18687753, PubMed Central PMCID: 2575909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Mathurin P, Louvet A, Duhamel A, Nahon P, Carbonell N, Boursier J, et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA. 2013;310(10):1033–41.

    Article  CAS  PubMed  Google Scholar 

  101. Sidhu SS, Goyal O, Singla P, Gupta D, Sood A, Chhina RS, et al. Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial). Dig Dis Sci. 2012;57(6):1664–71.

    Article  CAS  PubMed  Google Scholar 

  102. Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol. 2008;48(3):465–70.

    Article  CAS  PubMed  Google Scholar 

  103. Singh S, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology. 2015;149(4):958–70.e12.

    Article  CAS  PubMed  Google Scholar 

  104. Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A. Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci. 2011;15(9):1003–9.

    CAS  PubMed  Google Scholar 

  105. Bansal S, Wang W, Falk S, Schrier R. Combination therapy with albumin and pentoxifylline protects against acute kidney injury during endotoxemic shock in mice. Ren Fail. 2009;31(9):848–54.

    Article  CAS  PubMed  Google Scholar 

  106. Costantini TW, Loomis WH, Putnam JG, Drusinsky D, Deree J, Choi S, et al. Burn-induced gut barrier injury is attenuated by phosphodiesterase inhibition: effects on tight junction structural proteins. Shock. 2009;31(4):416–22. PubMed PMID: 18791495, PubMed Central PMCID: PMC3445035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Costantini TW, Loomis WH, Putnam JG, Kroll L, Eliceiri BP, Baird A, et al. Pentoxifylline modulates intestinal tight junction signaling after burn injury: effects on myosin light chain kinase. J Trauma. 2009;66(1):17–24. discussion -5, PubMed PMID: 19131801, PubMed Central PMCID: PMC4251583.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol. 2013;69(5):1057–73.

    Article  CAS  PubMed  Google Scholar 

  109. Wattanasirichaigoon S, Menconi MJ, Fink MP. Lisofylline ameliorates intestinal and hepatic injury induced by hemorrhage and resuscitation in rats. Crit Care Med. 2000;28(5):1540–9.

    Article  CAS  PubMed  Google Scholar 

  110. Wystrychowski W, Wystrychowski G, Zukowska-Szczechowska E, Obuchowicz E, Grzeszczak W, Wiecek A, et al. Nephroprotective effect of pentoxifylline in renal ischemia-reperfusion in rat depends on the timing of its administration. Transplant Proc. 2014;46(8):2555–7.

    Article  CAS  PubMed  Google Scholar 

  111. Gobejishvili L, Barve S, Breitkopf-Heinlein K, Li Y, Zhang J, Avila DV, et al. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4. J Pharmacol Exp Ther. 2013;347(1):80–90. PubMed PMID: 23887098, PubMed Central PMCID: PMC3781411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015;372(17):1619–28.

    Article  CAS  PubMed  Google Scholar 

  113. Hmoud BS, Patel K, Bataller R, Singal AK. Corticosteroids and occurrence of and mortality from infections in severe alcoholic hepatitis: a meta-analysis of randomized trials. Liver Int. 2016;36(5):721–8. doi: 10.1111/liv.12939. Epub 2015 Sep 14.

  114. Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17(7):751–9.

    Article  PubMed  Google Scholar 

  115. Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani G, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant. 2010;10(1):138–48.

    Article  CAS  PubMed  Google Scholar 

  116. Berlakovich GA. Challenges in transplantation for alcoholic liver disease. World J Gastroenterol. 2014;20(25):8033–9. PubMed PMID: 25009374, PubMed Central PMCID: PMC4081673.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Singal AK, Chaha KS, Rasheed K, Anand BS. Liver transplantation in alcoholic liver disease current status and controversies. World J Gastroenterol. 2013;19(36):5953–63. PubMed PMID: 24106395, PubMed Central PMCID: PMC3785616.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007;13:197–205.

    Article  PubMed  Google Scholar 

  119. Cuadrado A, Fabrega E, Casafont F, Pons-Romero F. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005;11(4):420–6.

    Article  PubMed  Google Scholar 

  120. Altamirano J, Bataller R. Cigarette smoking and chronic liver diseases. Gut. 2010;59(9):1159–62.

    Article  CAS  PubMed  Google Scholar 

  121. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758–69.

    Article  CAS  PubMed  Google Scholar 

  122. O’Shea RS, Dasarathy S, McCullough AJ. Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Alcoholic liver disease. Hepatology. 2010;51(1):307–28.

    Article  PubMed  Google Scholar 

  123. Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol. 2011;4(1):63–81. PubMed PMID: 21317995, PubMed Central PMCID: 3036962.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Mathurin P, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365(19):1790–800.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology & Nutrition, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA

    Ashutosh Barve M.D., Luis S. Marsano M.D., Dipendra Parajuli M.D., Matthew Cave M.D. & Craig J. McClain M.D.

  2. Robley Rex Louisville VAMC, Louisville, KY, USA

    Ashutosh Barve M.D., Luis S. Marsano M.D., Dipendra Parajuli M.D., Matthew Cave M.D. & Craig J. McClain M.D.

  3. Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Center for Translational Research Building, 505 South Hancock Street, Suite 503, Louisville, KY, 40292, USA

    Matthew Cave M.D. & Craig J. McClain M.D.

  4. Department of Biochemistry and Molecular Biology, University of Louisville School of Medicine, Louisville, KY, USA

    Matthew Cave M.D.

Authors
  1. Ashutosh Barve M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis S. Marsano M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dipendra Parajuli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew Cave M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Craig J. McClain M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig J. McClain M.D. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Kia Saeian

  2. Division of Gastroenterology and Hepatology, Medicine Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Reza Shaker

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Barve, A., Marsano, L.S., Parajuli, D., Cave, M., McClain, C.J. (2017). Alcoholic Liver Disease. In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30103-7_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30101-3

  • Online ISBN: 978-3-319-30103-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation